Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Sherry Winter

Sherry Winter

Senior Solution Marketing Manager

Connect with Sherry Winter on LinkedIn

About the author: As a Senior Solution Marketing Manager at Elsevier, Sherry is responsible for delivering insights on markets and customers, messaging, positioning and thought leadership for life science solutions, including PharmaPendium, that enable Drug Discovery and Development and Pharmacovigilance. Sherry has a PhD in Medical Genetics from the University of Toronto, Canada and has several years of experience in life science marketing and communications, having worked at QIAGEN in Hilden, Germany before joining Elsevier and also in Research Communications at the University Health Network in Toronto, Canada. Prior to this, Sherry performed research at cancer institutes in both Canada and the US.

Posts by Sherry Winter

Reducing Adverse Event Risk

Posted on September 25th, 2017 in Pharma R&D

In 2012, the U.S. Food and Drug Administration (FDA) provided draft guidance for the industry on drug interaction studies, stating that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development, as part of an adequate assessment of the drug’s safety and effectiveness.” (more…)

The Challenges of Signal Detection in Spontaneous Reporting

Posted on September 13th, 2017 in Pharmacovigilance

Pharmacovigilance is essential to pharmaceutical businesses. It facilitates the correct use of a drug, safeguarding the drug as a meaningful treatment option when the benefits it offers outweigh known risks, or measures can be taken to mitigate those risks. (more…)

Assessing DDI Risk in the Digital Age

Posted on August 9th, 2017 in Pharmacovigilance

pills pic for SD case study
In their 2012 Drug Regulations, the U.S. Food and Drug Administration recommended that “pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development.”


The Value of Drug–Drug Interaction Risk Assessments

Posted on June 28th, 2017 in Pharma R&D

Should a drug candidate move on to pre-clinical and clinical trials? It’s a question that every pharmaceutical developer must face, and the earlier they can answer it, the better in terms of use of time and effort. (more…)

  1. 1
  2. 2
  3. 3